MersV1, PubMed, Corpus, bibRecord, 002A81

Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?

Identifieur interne : 002A81 ( PubMed/Corpus ); précédent : 002A80; suivant : 002A82

Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?

Auteurs : I. Le Gall ; P. Millasseau ; J. Dausset ; D. Cohen

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1986.

RBID : pubmed:3464000

English descriptors

KwdEn :
- Alleles, Amino Acid Sequence, Exons, HLA-D Antigens (genetics), HLA-DR Antigens (genetics), HLA-DR Antigens (immunology), Histocompatibility Testing, Nucleic Acid Hybridization, Oligonucleotides (analysis), Polymorphism, Genetic.
MESH :
- chemical , analysis : Oligonucleotides.
- chemical , genetics : HLA-D Antigens, HLA-DR Antigens.
- chemical , immunology : HLA-DR Antigens.
- Alleles, Amino Acid Sequence, Exons, Histocompatibility Testing, Nucleic Acid Hybridization, Polymorphism, Genetic.

Abstract

Comparisons of exon II HLA-DR beta sequences have shown that nucleotide variations are principally clustered within the following three regions: V1 (amino acid 8-15), V2 (25-32), and V3 (70-77). V1, V2, and V3-derived 24-mers have been synthesized, the DR beta sequences coming from DR1, DR3, Drw6, DR4, DR5, and DRw53 haplotypes. Each oligonucleotide was hybridized to Pvu II-digested DNA samples from 13 HLA genotyped families; therefore, 52 haplotypes have been investigated. Six polymorphic Pvu II fragments were detected, constituting two allelic series probably corresponding to the beta 1 and beta 2 locus of the DR region. The first series (beta 1) comprises a minimum of nine alleles while the second series (beta 2), which is less polymorphic, comprises at least four alleles. Certain patterns correlate perfectly with certain DR specificities, whereas other patterns define new subdivisions as in DR3 and DRw6 haplotypes. Although it appears that some mismatches do not always prevent hybridization in the conditions used in this work, this method will provide in many instances a convenient tool for HLA-DR typing.

DOI: 10.1073/pnas.83.20.7836
PubMed: 3464000

Links to Exploration step

pubmed:3464000

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?</title>
<author><name sortKey="Le Gall, I" sort="Le Gall, I" uniqKey="Le Gall I" first="I" last="Le Gall">I. Le Gall</name>
</author>
<author><name sortKey="Millasseau, P" sort="Millasseau, P" uniqKey="Millasseau P" first="P" last="Millasseau">P. Millasseau</name>
</author>
<author><name sortKey="Dausset, J" sort="Dausset, J" uniqKey="Dausset J" first="J" last="Dausset">J. Dausset</name>
</author>
<author><name sortKey="Cohen, D" sort="Cohen, D" uniqKey="Cohen D" first="D" last="Cohen">D. Cohen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1986">1986</date>
<idno type="RBID">pubmed:3464000</idno>
<idno type="pmid">3464000</idno>
<idno type="doi">10.1073/pnas.83.20.7836</idno>
<idno type="wicri:Area/PubMed/Corpus">002A81</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?</title>
<author><name sortKey="Le Gall, I" sort="Le Gall, I" uniqKey="Le Gall I" first="I" last="Le Gall">I. Le Gall</name>
</author>
<author><name sortKey="Millasseau, P" sort="Millasseau, P" uniqKey="Millasseau P" first="P" last="Millasseau">P. Millasseau</name>
</author>
<author><name sortKey="Dausset, J" sort="Dausset, J" uniqKey="Dausset J" first="J" last="Dausset">J. Dausset</name>
</author>
<author><name sortKey="Cohen, D" sort="Cohen, D" uniqKey="Cohen D" first="D" last="Cohen">D. Cohen</name>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="1986" type="published">1986</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alleles</term>
<term>Amino Acid Sequence</term>
<term>Exons</term>
<term>HLA-D Antigens (genetics)</term>
<term>HLA-DR Antigens (genetics)</term>
<term>HLA-DR Antigens (immunology)</term>
<term>Histocompatibility Testing</term>
<term>Nucleic Acid Hybridization</term>
<term>Oligonucleotides (analysis)</term>
<term>Polymorphism, Genetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Oligonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>HLA-D Antigens</term>
<term>HLA-DR Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HLA-DR Antigens</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Alleles</term>
<term>Amino Acid Sequence</term>
<term>Exons</term>
<term>Histocompatibility Testing</term>
<term>Nucleic Acid Hybridization</term>
<term>Polymorphism, Genetic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Comparisons of exon II HLA-DR beta sequences have shown that nucleotide variations are principally clustered within the following three regions: V1 (amino acid 8-15), V2 (25-32), and V3 (70-77). V1, V2, and V3-derived 24-mers have been synthesized, the DR beta sequences coming from DR1, DR3, Drw6, DR4, DR5, and DRw53 haplotypes. Each oligonucleotide was hybridized to Pvu II-digested DNA samples from 13 HLA genotyped families; therefore, 52 haplotypes have been investigated. Six polymorphic Pvu II fragments were detected, constituting two allelic series probably corresponding to the beta 1 and beta 2 locus of the DR region. The first series (beta 1) comprises a minimum of nine alleles while the second series (beta 2), which is less polymorphic, comprises at least four alleles. Certain patterns correlate perfectly with certain DR specificities, whereas other patterns define new subdivisions as in DR3 and DRw6 haplotypes. Although it appears that some mismatches do not always prevent hybridization in the conditions used in this work, this method will provide in many instances a convenient tool for HLA-DR typing.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3464000</PMID>
<DateCompleted><Year>1986</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print"><Volume>83</Volume>
<Issue>20</Issue>
<PubDate><Year>1986</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?</ArticleTitle>
<Pagination><MedlinePgn>7836-40</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Comparisons of exon II HLA-DR beta sequences have shown that nucleotide variations are principally clustered within the following three regions: V1 (amino acid 8-15), V2 (25-32), and V3 (70-77). V1, V2, and V3-derived 24-mers have been synthesized, the DR beta sequences coming from DR1, DR3, Drw6, DR4, DR5, and DRw53 haplotypes. Each oligonucleotide was hybridized to Pvu II-digested DNA samples from 13 HLA genotyped families; therefore, 52 haplotypes have been investigated. Six polymorphic Pvu II fragments were detected, constituting two allelic series probably corresponding to the beta 1 and beta 2 locus of the DR region. The first series (beta 1) comprises a minimum of nine alleles while the second series (beta 2), which is less polymorphic, comprises at least four alleles. Certain patterns correlate perfectly with certain DR specificities, whereas other patterns define new subdivisions as in DR3 and DRw6 haplotypes. Although it appears that some mismatches do not always prevent hybridization in the conditions used in this work, this method will provide in many instances a convenient tool for HLA-DR typing.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Gall</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Millasseau</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dausset</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cohen</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006681">HLA-D Antigens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005091" MajorTopicYN="Y">Exons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006681" MajorTopicYN="N">HLA-D Antigens</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009693" MajorTopicYN="Y">Nucleic Acid Hybridization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year>
<Month>10</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1986</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1986</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">3464000</ArticleId>
<ArticleId IdType="pmc">PMC386817</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.83.20.7836</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Mar;82(5):1475-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3856276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1984 Sep 1;160(3):751-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6206187</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1985 May;82(10):3405-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3858829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(11):3794-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2582424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1985 Jul 1;162(1):105-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2409205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1985 Sep;135(3):2149-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2991381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1985 Aug;82(15):5165-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3860851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 1985 Jun;21(6):511-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3927474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1985 Sep 12-18;317(6033):166-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3875800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 1985 Jul;85:5-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2995241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1985 Nov;82(21):7197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3933002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1985 Nov;4(11):2839-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2998758</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>C R Acad Sci III. 1985;301(15):669-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3935278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1986 Feb 25;261(6):2738-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3456344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunogenetics. 1986;23(3):172-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3007347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1986 May 15;136(10):3767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3486222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1986 Apr;83(8):2642-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3458223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1983;2(3):389-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11894954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunochemistry. 1975 Sep;12(9):741-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">53191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1977 Jan 20;265(5591):248-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">834269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1979 Dec;76(12):6567-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">392522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1981 Nov;78(11):6613-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6171820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 1982;66:5-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6182090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1982 Nov 25;300(5890):372-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6292729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 1983 Jan 4;22(1):185-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6600932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1984 Jul;3(7):1655-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6589154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Immunol. 1984 Jul;10(3):143-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6430842</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Tissue Antigens. 1985 Feb;25(2):96-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2581334</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002A81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:3464000
   |texte=   Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:3464000" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?

Two DR beta allelic series defined by exon II-specific synthetic oligonucleotide genomic hybridization: a method of HLA typing?

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki